FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.
What happened
FDA inspected Higley Industries' drug manufacturing facility in Dyersville, Iowa, from September 19 to September 21, 2023. FDA found the firm did not adequately test incoming components such as ethanol for methanol and glycerin for diethylene glycol or ethylene glycol, and relied on supplier certificates without establishing their reliability. FDA also found missing process validation for hand sanitizer and inadequate quality unit oversight.
What FDA found
Failed to adequately test incoming ethanol for methanol and glycerin for diethylene glycol or ethylene glycol before use, and failed to show that water used as a component met the United States Pharmacopeia water standard.
21 CFR 211.84(d)(1) and (2)Failed to validate the manufacturing process and qualify equipment for the hand sanitizer; the firm said any filling line could be used but could not provide process validation documentation.
21 CFR 211.100(a)The quality unit did not ensure adequate evaluation of product quality before batch release, and the Quality Manual gave the Shipping Clerk final authority to review and approve drug product for release.
21 CFR 211.22(a)Batch production and control records did not document each significant manufacturing step for each drug product batch.
21 CFR 211.188(b)Failed to establish adequate written procedures for test methods and sampling plans, an adequate ongoing stability program, and periodic product reviews.
21 CFR 211.160(b), 211.166(a), 211.180(e)
What FDA wants
FDA asks the company to respond in writing within 15 working days describing what it has done to address the violations and prevent recurrence, and to state reasons and a completion schedule if corrective actions cannot be finished in that time.
Who should pay attention
- brands that buy OTC drugs or hand sanitizer from this contract manufacturer
- suppliers and distributors of ethanol or glycerin used in drugs
- quality teams at other OTC drug manufacturers
This is a summary. Read the original letter on fda.gov.